Exhibit 99.1

                                                      COMPANY CONTACT:

                                                      Rhonda F. Rhyne, President
                                                      rrhyne@cardiodynamics.com
                                                      800-778-4825, Ext. 1013

                   CARDIODYNAMICS INCREASES SALES FORCE BY 25%

SAN DIEGO--December 12, 2006--CardioDynamics (Nasdaq: CDIC), the innovator and
leader of BioZ(R) Impedance Cardiography (ICG) technology, today announced that
it has increased sales personnel by 25% to further enhance the steadily
increasing sales the Company has seen throughout the year.

The Company announced it had an average of 49 direct, non-managing sales
personnel, including 31 capital sales representatives and 18 clinical sensor
sales representatives in its fourth fiscal quarter, which ended November 30,
2006. The Company reported that it had recently increased non-managing sales
headcount by 12 sales personnel, or 25%, for a total of 61 direct selling
representatives.

"We were very pleased to see the steady progression in sales throughout 2006,
and were especially encouraged to see solid sales results from the
representatives we had hired in early to mid-2006," stated CardioDynamics' Chief
Executive Officer, Michael K. Perry. "To drive continued sales growth in 2007,
we decided it would be prudent to aggressively add headcount as early in our
fiscal year as possible. We now have increased sales capacity to efficiently
grow our top line and have taken actions to streamline our overall organization,
which should lead to improved operating results. We feel we have worked through
the challenges associated with the Medicare policy decision, incorporated
strategies with our current and prospective customers to more effectively
integrate the BioZ testing procedure, and are well positioned for 2007."



Perry concluded, "Our priorities for 2007 are to deliver improved revenue
performance, margins and customer satisfaction through the actions we have taken
over the past year and one-half. We will continue to make strategic investments
in our organization to help drive ICG to become a cardiovascular standard of
care."

ABOUT CARDIODYNAMICS:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
breakthrough medical technology called Impedance Cardiography (ICG). The Company
develops, manufactures and markets noninvasive diagnostic and monitoring
technologies and electrodes. The Company's ICG Systems are being used by
physicians around the world to help battle the number one killer of men and
women--cardiovascular disease. Partners include GE Healthcare and Philips
Medical Systems. For additional information, please refer to the company's Web
site at www.cdic.com.

FORWARD-LOOKING (SAFE HARBOR) STATEMENT:

Except for historical and factual information contained herein, this press
release contains forward-looking statements including anticipated improved
operating results, revenue performance, margins and customer satisfaction, the
accuracy of which is necessarily subject to uncertainties and risks including
the Company's primary dependence on the BioZ product line, and various
uncertainties characteristic of early growth companies, as well as other risks
detailed in the Company's filings with the SEC, including its 2005 Form 10-K.
The Company does not undertake to update the disclosures contained in this press
release.